Hippo pathway activation mediates chemotherapy-induced anti-cancer effect and cardiomyopathy through causing mitochondrial damage and dysfunction
Gang She(Xi'an Jiaotong University), Xiao‐Jun Du(Baker Heart and Diabetes Institute), Ru‐Yue Bai(Xi'an Jiaotong University), Jin-Chan Du(Xi'an Jiaotong University), Zheng‐Da Pang(Xi'an Jiaotong University), Xiu‐Ling Deng(Xi'an Jiaotong University), Tian-Tian Pu(Xi'an Jiaotong University), Junichi Sadoshima(Rutgers, The State University of New Jersey), Yi Zhang(University of Southern California), Yu Zhang(Jinzhou Medical University), Hui‐Fang Wang(Xi'an Jiaotong University), Wei Wu, Yujie Ren(Wenzhou Medical University)
Cited by 61
Related Papers
The ORF3a protein of SARS-CoV-2 induces apoptosis in cells
|Cellular and Molecular Immunology|2020|514
Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19
|Immunity|2020|387
Plasma metabolomic and lipidomic alterations associated with COVID-19
|National Science Review|2020|367
Nicotinamide Mononucleotide, an Intermediate of NAD+ Synthesis, Protects the Heart from Ischemia and Reperfusion
|PLoS ONE|2014|295
Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy
|Journal of Clinical Investigation|2003|277